Latest Hotspot

Ranok Therapeutics Expands RNK05047 Clinical Trials to China

15 March 2024
3 min read

Ranok Therapeutics, an emerging enterprise at the clinical phase in the biopharmaceutical industry, has unveiled the commencement of administering doses to participants in China as part of an early-phase clinical trial. This trial is for RNK05047, which represents the company's initial foray into the development of breakthrough protein degraders. These innovative therapeutics are designed to selectively dismantle specific proteins to combat various oncological conditions.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The investigation, a counterpart to a currently active early-stage trial in the United States, aims to assess the harmlessness, tolerability, as well as the absorption and action mechanics of RNK05047 in Chinese individuals who are grappling with progressed malignancies or lymphatic system cancers. Ranok forecasts that early findings from the initial-stage inquiries in both the United States and China will be accessible by the closing of the year 2024.

"RNK05047, conceived via Ranok's exclusive CHAMP technique, represents the pioneering BRD4-specific protein degrader to be examined clinically within Chinese borders. This expands our existing clinical research of RNK05047 from the U.S. to include Asian patients, which we anticipate will yield significant understanding," stated Weiwen Ying, Ph.D., the founder and CEO of Ranok.

"BRD4 stands as an epigenetic focal point of significant interest in the realm of cancer therapy, applicable across diverse cancer manifestations," voiced Ning Li, M.D., Professor and VP at the National Cancer Center/Cancer Hospital, "The Cancer Hospital, trailblazing in both magnitude and reputation within China for cancer diagnosis and therapy, is thrilled to partake in this study with the prospect that RNK05047 will emerge as a valuable new treatment avenue for those suffering from cancer."

The Phase 1 clinical experiment, steered by Timothy Yap, M.D., Ph.D., a professor specializing in Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, is meticulously crafted to affirm the initial concept utilizing SNV1521 through an oral, single-agent dose advancement and early effectiveness enlargement study. PARP inhibition is medically acknowledged for treating cancers fueled by homologous recombination insufficiency.

Nonetheless, the tolerability profile of the original class of PARP1 inhibitors constrains the overall potential of this category, especially when utilized in tandem with chemotherapeutic agents or cutting-edge compounds. Studies on preclinical test subjects have revealed that focused targeting of PARP1 has the potential to magnify the therapeutic success and harmlessness of these inhibitors.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of March 12, 2024, there are 82 investigational drugs for the BRD4 target, including 67 indications, 68 R&D institutions involved, with related clinical trials reaching 55, and as many as 2585 patents.

RNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranok’s proprietary approach to targeted protein degradation, CHAMP. The active indications for RNK05047 include advanced malignant solid neoplasm, diffuse large B-cell lymphoma, lymphoma, and solid tumors. Further research and development will be needed to determine the safety and efficacy of this drug in treating these conditions.

图形用户界面, 文本, 应用程序

描述已自动生成

How to Effectively Search for Budesonide on Synapse
Drug Insights
2 min read
How to Effectively Search for Budesonide on Synapse
15 March 2024
Budesonide, a small molecule drug with a strong ability to bind to the glucocorticoid receptor (GR) as an agonist, was approved as early as 1981 and has been on the market for more than 40 years.
Read →
ASLAN Pharmaceuticals Provides TREK-DX Update, Highlights Eblasakimab's Success in Dupilumab-Treated Atopic Dermatitis Cases
Latest Hotspot
3 min read
ASLAN Pharmaceuticals Provides TREK-DX Update, Highlights Eblasakimab's Success in Dupilumab-Treated Atopic Dermatitis Cases
14 March 2024
ASLAN Pharmaceuticals Offers Update on TREK-DX Research and Emphasizes Eblasakimab's Effectiveness for Patients with Atopic Dermatitis Previously Treated with Dupilumab.
Read →
Targeted GPRC5D CAR-T Product: OriCAR-017
Targeted GPRC5D CAR-T Product: OriCAR-017
14 March 2024
In January, Oricell Therapeutics announced U.S. FDA approval for the IND application of OriCAR-017 to treat relapsed/refractory multiple myeloma (R/R MM).
Read →
MoonLake's Sonelokimab Shows Promising Six-Month Results for Psoriatic Arthritis Treatment at R&D Event
Latest Hotspot
3 min read
MoonLake's Sonelokimab Shows Promising Six-Month Results for Psoriatic Arthritis Treatment at R&D Event
14 March 2024
MoonLake reveals notable advancements using Nanobody® sonelokimab over a six-month period for treating active psoriatic arthritis (PsA), along with other crucial updates during its research and development event.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.